Correction of Sickle Cell Disease in Adult Mice by Interference with Fetal Hemoglobin Silencing
Open accessThe DOI matches its Crossref record; 44 of the 45 references it cites were found in a registry or an index.
Abstract
Manipulation of a transcriptional repressor promotes expression of protective fetal globin genes.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“However, the degree of γ -globin induction is substantially less than that seen with BCL11A de fi ciency (8).”
From Corepressor-dependent silencing of fetal hemoglobin expression by BCL11A (2013) · cites this paper as [8]
In the citing paper
“Reducing bcl11a expression in transgenic sickle mice derepressed g-globin genes.17,18”
From Fetal hemoglobin in sickle cell anemia (2020) · cites this paper as [18]
In the citing paper
“However, deletion of BCL11A in mouse results in much greater increases (31.2- to 232.9-fold) of embryonic globin genes in de fi nitive fetal liver and bone marrow erythroid cells (Fig. 4 C and E ) (8)”
From Corepressor-dependent silencing of fetal hemoglobin expression by BCL11A (2013) · cites this paper as [8]
In the citing paper
“Most importantly, inactivation of BCL11A alone is suf fi cient to ameliorate the hematologic and pathologic defects associated with SCD through high-level HbF induction in humanized mouse models (8).”
From Corepressor-dependent silencing of fetal hemoglobin expression by BCL11A (2013) · cites this paper as [8]
In the citing paper
“DNA methylation plays an important role in globin gene expression, and DNA demethylating agents have been shown to induce HbF expression in various model systems and patients (8, 17, 18).”
From Corepressor-dependent silencing of fetal hemoglobin expression by BCL11A (2013) · cites this paper as [8]
2 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
DAVID: Database for Annotation, Visualization, and Integrated Discovery
Dennis, G., Sherman, B. T., Hosack, D. A., Yang, J., Gao, W., Lane, H. C., & Lempicki, R. A. (2003) · Genome Biology · doi:10.1186/gb-2003-4-5-p3 · Cited by 9,327
Mortality in sickle cell disease. Life expectancy and risk factors for early death
Platt, O. S., Brambilla, D. J., Rosse, W. F., Milner, P. F., Castro, O., Steinberg, M. H., & Klug, P. P. (1994) · New England Journal of Medicine · doi:10.1056/nejm199406093302303 · Cited by 3,320
Model-based analysis of oligonucleotide arrays: Expression index computation and outlier detection.
Li, C., & Wong, W. H. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.98.1.31 · Cited by 3,133
Inducible Gene Targeting in Mice
Kühn, R., Schwenk, F., Aguet, M., & Rajewsky, K. (1995) · Science · doi:10.1126/science.7660125 · Cited by 1,641
Therapeutic silencing of microRNA-122 in primates with chronic hepatitis C virus infection
Lanford, R. E., Hildebrandt-Eriksen, E. S., Petri, A., Persson, R., Lindow, M., Munk, M. E., Kauppinen, S., & Ørum, H. (2010) · Science · doi:10.1126/science.1178178 · Cited by 1,459
Treatment of sickle cell anemia mouse model with iPS cells generated from autologous skin
Hanna, J., Wernig, M., Markoulaki, S., Sun, C.-W., Meissner, A., Cassady, J. P., Beard, C., Brambrink, T., Wu, L.-C., Townes, T. M., et al. (2007) · Science · doi:10.1126/science.1152092 · Cited by 1,202
Human Fetal Hemoglobin Expression Is Regulated by the Developmental Stage-Specific Repressor BCL11A
Sankaran, V. G., Menne, T. F., Xu, J., Akie, T. E., Lettre, G., Van Handel, B., Mikkola, H. K. A., Hirschhorn, J. N., Cantor, A. B., & Orkin, S. H. (2008) · Science · doi:10.1126/science.1165409 · Cited by 919
Self-citationA Specific Chemical Difference Between the Globins of Normal Human and Sickle-Cell Anæmia Hæmoglobin
INGRAM, V. M. (1956) · Nature · doi:10.1038/178792a0 · Cited by 896
Direct inhibition of the NOTCH transcription factor complex
Moellering, R. E., Cornejo, M., Davis, T. N., Bianco, C. D., Aster, J. C., Blacklow, S. C., Kung, A. L., Gilliland, D. G., Verdine, G. L., & Bradner, J. E. (2009) · Nature · doi:10.1038/nature08543 · Cited by 752
Peculiar elongated and sickle-shaped red blood corpuscles in a case of severe anemia. 1910.
Jb, H. (2001) · PubMed Central · Cited by 676
Cited by
Items 101–200 of 327
Sickle cell disease: progress towards combination drug therapy
Pace, B. S., Starlard‐Davenport, A., & Kutlar, A. (2021) · British Journal of Haematology · doi:10.1111/bjh.17312 · Cited by 57
“Moreover, Xu et al.(101) demonstrated that erythroid-specific knockout of BCL11A in SCD mice results in higher HbF expression, which was enhanced further with epigenetic modifiers, such as the histone deacetylase inhibitor suberoylanilide hydroxamic acid, and the DNMT1 inhibitor 5-azacytidine.”
BackgroundSwitching from fetal to adult hemoglobin
Wang, X., & Thein, S. L. (2018) · Nature Genetics · doi:10.1038/s41588-018-0094-z · Cited by 55
Walters, R., Vasilaki, E., Aman, J., Chen, C.-N., Wu, Y., Liang, O. D., Ashek, A., Dubois, O., Zhao, L., Sabrin, F., et al. (2023) · Circulation · doi:10.1161/circulationaha.122.061940 · Cited by 48
“Confirmed examples of variation in enhancer regions causing disease are few, including BCL11 in sickle cell disease (25) and FTO in obesity (26).”
BackgroundFetal hemoglobin regulation in β-thalassemia: heterogeneity, modifiers and therapeutic approaches
Sripichai, O., & Fucharoen, S. (2016) · Expert Review of Hematology · doi:10.1080/17474086.2016.1255142 · Cited by 54
“knockout mouse embryos harboring an entire human β-globin locus (β-YAC) transgene [53].”
BackgroundHarteveld, C. L. (2013) · International Journal of Laboratory Hematology · doi:10.1111/ijlh.12108 · Cited by 48
“The hemoglobin switch, which is both tissue- and stage specific, has been matter of extensive investigation as this should hold the key to gene therapy [11–13].”
BackgroundThe genetics of human hematopoiesis and its disruption in disease
Bao, E. L., Cheng, A. N., & Sankaran, V. G. (2019) · EMBO Molecular Medicine · doi:10.15252/emmm.201910316 · Cited by 42
“This approach thus performs a per-gene or per-region association study as opposed to per-variant association tests in GWAS (Lee et al, 2012; Zuk et al, 2014).”
MethodSelf-citationZhang, H., Wang, S., Liu, D., Gao, C., Han, Y., Guo, X., Qu, X., Li, W., Zhang, S., Geng, J., et al. (2021) · Blood · doi:10.1182/blood.2021011410 · Cited by 47
Krishnamoorthy, S., Pace, B. S., Gupta, D., Sturtevant, S., Li, Y., Makala, L., Brittain, J. E., Moore, N., Vieira, B. F., Thullen, T. D., et al. (2017) · JCI Insight · doi:10.1172/jci.insight.96409 · Cited by 50
“Strategies to reactivate γ-globin expression have been used successfully in mouse models of SCD to ameliorate the disease phenotype (18).”
BackgroundRoosjen, M., McColl, B., Kao, B., Gearing, L. J., Blewitt, M. E., & Vadolas, J. (2013) · The FASEB Journal · doi:10.1096/fj.13-242669 · Cited by 50
Hemoglobin genetics: recent contributions of GWAS and gene editing
Smith, E. C., & Orkin, S. H. (2016) · Human Molecular Genetics · doi:10.1093/hmg/ddw170 · Cited by 45
“In this setting conditional inactivation of BCL11A in the erythroid lineage alone is sufficient to rescue hematological parameters in the disease model due to high-level, pancellular HbF expression (18).”
BackgroundSelf-citationDual function NFI factors control fetal hemoglobin silencing in adult erythroid cells
Qin, K., Huang, P., Feng, R., Keller, C. A., Peslak, S. A., Khandros, E., Saari, M. S., Lan, X., Mayuranathan, T., Doerfler, P. A., et al. (2022) · Nature Genetics · doi:10.1038/s41588-022-01076-1 · Cited by 46
“5), which is insufficient to account for the observed high HBG induction in these cells.”
Transcriptional Mechanisms Underlying Hemoglobin Synthesis
Katsumura, K. R., DeVilbiss, A., Pope, N. J., Johnson, K. D., & Bresnick, E. H. (2013) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a015412 · Cited by 50
“The conditional knockout of Bcl11a using EpoR-Creþ mice crossed to b-YAC transgenic mice prevented complete silencing of human g-globin from the b-YAC (Xu et al. 2011).”
BackgroundHumbert, O., Peterson, C. W., Norgaard, Z. K., Radtke, S., & Kiem, H.-P. (2018) · Molecular Therapy - Methods & Clinical Development · doi:10.1016/j.omtm.2017.11.005 · Cited by 43
Translating CRISPR-Cas Therapeutics: Approaches and Challenges
Tay, L. S., Palmer, N. D., Panwala, R., Chew, W. L., & Mali, P. (2020) · The CRISPR Journal · doi:10.1089/crispr.2020.0025 · Cited by 47
“Disruption of BCL11A de-represses fetal hemoglobin expression and rescues sickle-cell defects.(42,43) Another”
Mehta, S., Buyanbat, A., Yan, K., Karayel, Ö., Goldman, S. R., Seruggia, D., Zhang, K., Fujiwara, Y., Donovan, K. A., Zhu, Q., et al. (2022) · Cell chemical biology · doi:10.1016/j.chembiol.2022.06.007 · Cited by 45
Self-citationBCL11A enhancer haplotypes and fetal hemoglobin in sickle cell anemia
Sebastiani, P., Farrell, J. J., Alsultan, A., Wang, S., Edward, H. L., Shappell, H., Bae, H., Milton, J. N., Baldwin, C. T., Al-Rubaish, A. M., et al. (2015) · Blood Cells, Molecules, and Diseases · doi:10.1016/j.bcmd.2015.01.001 · Cited by 41
“One trans-acting element is BCL11A, a repressor of γ-globin gene expression [10,17–21].”
BackgroundThe emerging role of fetal hemoglobin induction in non-transfusion-dependent thalassemia
Thein, S. L. (2012) · Blood Reviews · doi:10.1016/s0268-960x(12)70011-5 · Cited by 45
Gene Therapy of the Hemoglobinopathies
Kunz, J. B., & Kulozik, A. E. (2020) · HemaSphere · doi:10.1097/hs9.0000000000000479 · Cited by 42
Mouse models of sickle cell disease: Imperfect and yet very informative
Kamimura, S., Smith, M. L., Vogel, S., Almeida, L. E. F., Thein, S. L., & Quezado, Z. (2023) · Blood Cells Molecules and Diseases · doi:10.1016/j.bcmd.2023.102776 · Cited by 40
CRISPR-Cas Technology as a Revolutionary Genome Editing tool: Mechanisms and Biomedical Applications
Ebrahimi, S., Khosravi, M. A., Raz, A., Karimipoor, M., & Parvizi, P. (2023) · ̒Ulūm va funūn-i bastah/bandī · doi:10.61186/ibj.27.5.219 · Cited by 48
Genetic therapies for sickle cell disease
Esrick, E. B., & Bauer, D. E. (2018) · Seminars in Hematology · doi:10.1053/j.seminhematol.2018.04.014 · Cited by 41
Self-citationChou, Y., Chen, R.-L., Lai, Z.-S., Song, J., Chao, Y., & Shen, C.-K. J. (2015) · Molecular and Cellular Biology · doi:10.1128/mcb.00035-15 · Cited by 42
Locus-Specific Proteomics by TChP: Targeted Chromatin Purification
Pourfarzad, F., Aghajanirefah, A., de Boer, E., ten Have, S., van Dijk, T. B., Kheradmandkia, S., Stadhouders, R., Thongjuea, S., Soler, É., Gillemans, N., et al. (2013) · Cell Reports · doi:10.1016/j.celrep.2013.07.004 · Cited by 44
Pharmacological and molecular approaches for the treatment of β‐hemoglobin disorders
Lohani, N., Bhargava, N., Munshi, A., & Ramalingam, S. (2017) · Journal of Cellular Physiology · doi:10.1002/jcp.26292 · Cited by 40
“This was further corroborated by subsequent studies in mice model for SCD, which showed that knockdown of BCL11A in transgenic SCD mice stimulated therapeutic levels of HbF (Xu et al., 2011).”
BackgroundResultHydroxyurea-inducible SAR1 gene acts through the Giα/JNK/Jun pathway to regulate γ-globin expression
Zhu, J., Chin, K., Aerbajinai, W., Kumkhaek, C., Li, H., & Rodgers, G. P. (2014) · Blood · doi:10.1182/blood-2013-10-534842 · Cited by 41
Induction of Fetal HemoglobinIn VivoMediated by a Syntheticγ-Globin Zinc Finger Activator
Costa, F. C., Fedosyuk, H., Neades, R. Y., Rios, J. B. D. L., Barbas, C. F., & Peterson, K. R. (2012) · Anemia · doi:10.1155/2012/507894 · Cited by 39
Gudmundsdottir, B., Gudmundsson, K. O., Klarmann, K. D., Singh, S. K., Sun, L., Singh, S., Du, Y., Coppola, V., Stockwin, L. H., Nguyen, N., et al. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.05.043 · Cited by 38
Molecular Medicine: Found in Translation
Orkin, S. H. (2021) · Med · doi:10.1016/j.medj.2020.12.011 · Cited by 39
Self-citationCRISPR/Cas-based gene editing in therapeutic strategies for beta-thalassemia
Zeng, S., Lei, S.-Y., Qu, C., Wang, Y., Teng, S., & Huang, P. C. (2023) · Human Genetics · doi:10.1007/s00439-023-02610-9 · Cited by 38
“…analysis identified three loci related to HbF protein expression: BCL11A , HBS1L-MYB , and the HBB gene cluster (Lettre et al. 2008; Uda et al. 2008), of which the transcriptional repressor BCL11A negatively regulates HbF expression (Psatha et al. 2021; Sankaran et al. 2008, 2011; Xu et al. 2011).”
BackgroundPereira, C., Relvas, L., Bento, C., Abade, A., Ribeiro, L., & Manco, L. (2015) · Blood Cells Molecules and Diseases · doi:10.1016/j.bcmd.2015.02.001 · Cited by 40
“Xu et al [29] using a sickle cell disease mouse model demonstrate that interference with BCL11A function increases fetal hemoglobin levels and, thereby, reduces the severity of the disease.”
BackgroundGenome-wide association studies of hematologic phenotypes: a window into human hematopoiesis
Sankaran, V. G., & Orkin, S. H. (2013) · Current Opinion in Genetics & Development · doi:10.1016/j.gde.2013.02.006 · Cited by 33
“More recent studies have shown that ablation of Bcl11a leads to substantial reactivation of HbF expression and amelioration of SCD phenotypes in mouse models [17], supporting the findings from studies of HbF-associated genetic variants in SCD patients [15].”
ResultSelf-citationKing, A. J., & Higgs, D. R. (2018) · Hematology · doi:10.1182/asheducation-2018.1.353 · Cited by 40
“By contrast, knockout of BCL11A causes no discernible erythroid phenotype apart from its effects on globin expression.(28) In addition, recent identification of an erythroid-specific BCL11A enhancer provides an attractive target for gene editing, causing erythroid knockdown of BCL11A while preserving normal B-cell fun…”
BackgroundCRISPR-based therapeutic genome editing for inherited blood disorders
Levesque, S., & Bauer, D. E. (2025) · Nature Reviews Drug Discovery · doi:10.1038/s41573-025-01236-y · Cited by 39
Genetic modifiers of long‐term survival in sickle cell anemia
Wonkam, A., Chimusa, E. R., Mnika, K., Pule, G. D., Bitoungui, V. J. N., Mulder, N., Shriner, D., Rotimi, C. N., & Adeyemo, A. (2020) · Clinical and Translational Medicine · doi:10.1002/ctm2.152 · Cited by 37
Animal models of β-hemoglobinopathies: utility and limitations
McColl, B., & Vadolas, J. (2016) · Journal of Blood Medicine · doi:10.2147/jbm.s87955 · Cited by 37
Altrock, P. M., Brendel, C., Renella, R., Orkin, S. H., Williams, D. A., & Michor, F. (2016) · American Journal of Hematology · doi:10.1002/ajh.24449 · Cited by 30
“[7], who assessed RBC survival via biotin labeling of RBCs in SCD mice (S) and in control mice (non-S).”
BackgroundMethodSelf-citationGenome Editing for β-Hemoglobinopathies: Advances and Challenges
Frati, G., & Miccio, A. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10030482 · Cited by 36
“Interestingly, erythroid-specific inactivation of BCL11A ensures high-level, pancellular HbF expression, preventing disease manifestations in a β-YAC humanized mouse model of SCD [82].”
BackgroundEpigenetic Insights and Potential Modifiers as Therapeutic Targets in β–Thalassemia
Zakaria, N. A., Islam, M. A., Abdullah, W. Z., Bahar, R., Yusoff, A. A. M., Wahab, R. A., Shamsuddin, S., & Johan, M. F. (2021) · Biomolecules · doi:10.3390/biom11050755 · Cited by 37
“Additionally, robust HbF induction through the inactivation of BCL11A in humanized SCD mice corrects SCD-associated hematologic and pathologic defects [29].”
BackgroundDiverse Approaches to Gene Therapy of Sickle Cell Disease
White, S. L., Hart, K. L., & Kohn, D. B. (2022) · Annual Review of Medicine · doi:10.1146/annurev-med-042921-021707 · Cited by 35
Breaking genetic shackles: The advance of base editing in genetic disorder treatment
Xu, F., Zheng, C., Xu, W., Zhang, S., Liu, S., Chen, X., & Yao, K. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1364135 · Cited by 34
“The persistent presence of fetal hemoglobin (HbF), comprised of γ -globin and α -globin, is closely correlated with the severity of SCD and β -thalassemia (Xu et al., 2011; Bauer et al., 2013; Canver et al., 2015).”
BackgroundGenome editing strategies for fetal hemoglobin induction in beta-hemoglobinopathies
Demirci, S., Leonard, A. K., & Tisdale, J. F. (2020) · Human Molecular Genetics · doi:10.1093/hmg/ddaa088 · Cited by 33
“3% of total β-like human globins in adult SCD/Bcl11a−/− mice compared with SCD mice) (38).”
BackgroundCorepressor Rcor1 is essential for murine erythropoiesis
Yao, H., Goldman, D. C., Nechiporuk, T., Kawane, S., McWeeney, S. K., Tyner, J. W., Fan, G., Kerenyi, M. A., Orkin, S. H., Fleming, W., et al. (2014) · Blood · doi:10.1182/blood-2013-11-538678 · Cited by 34
Self-citationGene Therapy for β-Hemoglobinopathies: From Discovery to Clinical Trials
Segura, E., Ayoub, P. G., Hart, K. L., & Kohn, D. B. (2023) · Viruses · doi:10.3390/v15030713 · Cited by 35
“Studies showed that knocking out BCL11A in mouse models not only corrected sickle cell disease phenotypes but also mitigated disease symptoms [67].”
BackgroundLee, B.-S., Lee, B., Iyer, V. R., Sleckman, B. P., Shaffer, A. L., Ippolito, G. C., Tucker, H. O., & Dekker, J. D. (2017) · Molecular and Cellular Biology · doi:10.1128/mcb.00362-17 · Cited by 32
“exon 1 of the Bcl11a gene (Bcl11aL/L) (27, 31, 35).”
Self-citationWang, F., Ling, L., & Yu, D. (2021) · The American Journal of the Medical Sciences · doi:10.1016/j.amjms.2021.02.011 · Cited by 34
Liu, B., Brendel, C., Vinjamur, D. S., Zhou, Y., Harris, C. E., McGuinness, M. K., Manis, J. P., Bauer, D. E., Xu, H., & Williams, D. A. (2022) · Molecular Therapy · doi:10.1016/j.ymthe.2022.05.002 · Cited by 30
Evolution of nanobodies specific for BCL11A
Yin, M., Izadi, M., Tenglin, K., Viennet, T., Zhai, L., Zheng, G., Arthanari, H., Dassama, L. M. K., & Orkin, S. H. (2023) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2218959120 · Cited by 30
“Preclinical studies identified BCL11A as a regulator of HbF through genome-wide association studies (33, 34), knockout experiments in mice (35), and gene editing in erythroid cells (36–39).”
BackgroundSelf-citationPrecision Editing as a Therapeutic Approach for β-Hemoglobinopathies
Paschoudi, K., Yannaki, E., & Psatha, N. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24119527 · Cited by 34
Liu, L., Pertsemlidis, A., Ding, L.-H., Story, M. D., Steinberg, M. H., Sebastiani, P., Hoppe, C. C., Ballas, S. K., & Pace, B. S. (2016) · Experimental Biology and Medicine · doi:10.1177/1535370216642047 · Cited by 33
“BCL11A is a stage-specific repressor of g-globin expression in human primary erythroid progenitors(55) and mediates HBG1/HBG2 gene silencing in adult sickle cell transgenic mice.(56) The gene silencing effect involves reconfiguration of the HBB locus through interactions of BCL11A with GATA1, FOG1, and SOX6, as well a…”
BackgroundA survey of genetic fetal-haemoglobin modifiers in Nigerian patients with sickle cell anaemia
Adeyemo, T. A., Ojewunmi, O. O., Oyetunji, I. A., Rooks, H., Rees, D. C., Akinsulie, A., Akanmu, S. A., Thein, S. L., & Menzel, S. (2018) · PLoS ONE · doi:10.1371/journal.pone.0197927 · Cited by 31
“Findings from genetic studies can provide guidance for new therapeutic approaches [19, 20].”
BackgroundFetal Hemoglobin Regulation in Beta-Thalassemia
Lu, H. Y., Orkin, S. H., & Sankaran, V. G. (2023) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2022.12.002 · Cited by 30
Self-citationIqbal, M., Reljic, T., Corbacioglu, S., de la Fuente, J., Gluckman, É., Kumar, A., Yassine, F., Ayala, E., El-Jawahri, A. R., Murthy, H. S., et al. (2020) · Transplantation and Cellular Therapy · doi:10.1016/j.jtct.2020.10.007 · Cited by 30
Woodard, K. J., Doerfler, P. A., Mayberry, K. D., Sharma, A., Levine, R. M., Yen, J. S., Valentine, V. A., Palmer, L. E., Valentine, M. B., & Weiss, M. J. (2022) · Disease Models & Mechanisms · doi:10.1242/dmm.049463 · Cited by 27
“Interestingly, germline erythroid-specific ablation of the endogenous Bcl11a gene in Townes mice caused induction of HbF from 1% at baseline to ∼ 28% (Xu et al., 2011), contrasting with the current study showing only 3.5% HbF after disrupting the HBG1 promoter BCL11A binding motif at an average…”
InfluentialGenomic approaches to identifying targets for treating β hemoglobinopathies
Ngo, D., & Steinberg, M. H. (2015) · BMC Medical Genomics · doi:10.1186/s12920-015-0120-2 · Cited by 32
Promise of gene therapy to treat sickle cell disease
Romero, Z. G., DeWitt, M. A., & Walters, M. C. (2018) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2018.1536119 · Cited by 29
“A conditional knockout of BCL11A can correct the sickle phenotype in a mouse model of SCD [98].”
BackgroundCRISPR-Cas9 interrogation of a putative fetal globin repressor in human erythroid cells
Chung, J. E., Magis, W., Vu, J. T., Heo, S., Wartiovaara, K., Walters, M. C., Kurita, R., Nakamura, Y., Boffelli, D., Martin, D. I. K., et al. (2019) · PLoS ONE · doi:10.1371/journal.pone.0208237 · Cited by 27
“expression in adult-stage erythrocytes (14, 15), leads to high-level expression of g-globin.”
BackgroundProgress and challenges in CRISPR-mediated therapeutic genome editing for monogenic diseases
Konishi, C. T., & Long, C. (2021) · Journal of Biomedical Research · doi:10.7555/jbr.34.20200105 · Cited by 28
“Individuals with hereditary persistence of fetal globin (HPFH), a condition in which HbF is not silenced following birth, are largely protected by the deleterious outcomes of SCD or β-thalassemia[53].”
BackgroundHydroxyurea treatment in β-thalassemia patients: to respond or not to respond?
Banan, M. (2013) · Annals of Hematology · doi:10.1007/s00277-012-1671-3 · Cited by 32
“In addition, BCL11A knockout induces γglobin expression in human β-locus transgenic mice [91, 92].”
BackgroundBCL11A-deficient human erythropoiesis is impaired in vitro and after xenotransplantation into mice
Jang, Y., Feng, R., Palmer, L. E., Mayuranathan, T., Yao, Y., Mayberry, K. D., Zhou, S., Xu, J., Gossett, J. M., Kang, G., et al. (2025) · Blood Advances · doi:10.1182/bloodadvances.2024015574 · Cited by 25
“19 However, some erythroid functions of BCL11A may re fl ect evolutionary adaptations that have not occurred in mice, similar to the existence of fetal γ -globin genes and their regulation by hypoxia inducible factor-1.”
Self-citationDemirci, S., Zeng, J., Palchaudhuri, R., Wu, C., Abraham, D. M., Hayal, T. B., Essawi, K., Nguyen, M. A., Stasula, U., Chu, R., et al. (2024) · Cell stem cell · doi:10.1016/j.stem.2024.10.014 · Cited by 25
Yuan, Y., Zhou, Q., WAN, H., Shen, B., Wang, X., Wang, M., Feng, C., Xie, M., Gu, T., Zhou, T., et al. (2015) · Cell Research · doi:10.1038/cr.2015.74 · Cited by 25
Advances in therapeutic application of CRISPR-Cas9
Sun, J., Wang, J., Zheng, D., & Hu, X. (2019) · Briefings in Functional Genomics · doi:10.1093/bfgp/elz031 · Cited by 26
Tough decoy targeting of predominant let-7 miRNA species in adult human hematopoietic cells
de Vasconcellos, J. F., Byrnes, C., Lee, Y. T., Allwardt, J. M., Kaushal, M., Rabel, A., & Miller, J. L. (2017) · Journal of Translational Medicine · doi:10.1186/s12967-017-1273-x · Cited by 26
“The B-cell CLL/lymphoma 11A (BCL11A) is a zinc-finger transcription factor known to regulate gamma-globin and HbF levels in human erythroid cells [32] as well as to rescue the sickle cell disease phenotype in a murine model through the activation of HbF [33].”
BackgroundAdvances in Sickle Cell Therapies in the Hydroxyurea Era
Field, J. J., & Nathan, D. G. (2014) · Molecular Medicine · doi:10.2119/molmed.2014.00187 · Cited by 27
Pule, G. D., Bitoungui, V. J. N., Chemegni, B. C., Kengne, A. P., Antonarakis, S. E., & Wonkam, A. (2015) · OMICS A Journal of Integrative Biology · doi:10.1089/omi.2015.0124 · Cited by 27
“Specifically, variations in BCL11A have been shown to be amenable to therapeutic manipulation, leading to the reversal of SCD symptoms in mice models (Xu et al., 2011).”
BackgroundRecent advancements in gene therapy for sickle cell disease and β-thalassemia
Li, L., & Mandal, P. K. (2024) · Frontiers in Hematology · doi:10.3389/frhem.2024.1468952 · Cited by 29
“Suppressing BCL11A boosts g -globin production, leading to a rise in HbF (131).”
BackgroundA tetramer of BCL11A is required for stable protein production and fetal hemoglobin silencing
Zheng, G., Yin, M., Mehta, S., Chu, I.-T., Wang, S., Alshaye, A., Drainville, K., Buyanbat, A., Bienfait, F., Tenglin, K., et al. (2024) · Science · doi:10.1126/science.adp3025 · Cited by 22
Self-citationLIN28A Expression Reduces Sickling of Cultured Human Erythrocytes
de Vasconcellos, J. F., Fasano, R. M., Lee, Y. T., Kaushal, M., Byrnes, C., Meier, E. R., Anderson, M., Rabel, A., Braylan, R. C., Stroncek, D. F., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0106924 · Cited by 23
“BCL11A was previously associated with the human genetic variation in HbF levels [6,7,9,24], the regulation of HbF in adult erythroid cells [10], and the amelioration of the SCD phenotype in adult mice models of the disease [11].”
BackgroundTherapeutic gene editing strategies using CRISPR-Cas9 for the β-hemoglobinopathies
Papizan, J. B., Porter, S. N., Sharma, A., & Pruett‐Miller, S. M. (2020) · Journal of Biomedical Research · doi:10.7555/jbr.34.20200096 · Cited by 25
Ali, G., Tariq, M. A., Shahid, K., Ahmad, F. J., & Akram, J. (2020) · Gene Therapy · doi:10.1038/s41434-020-0153-9 · Cited by 29
Biology of Erythropoiesis, Erythroid Differentiation, and Maturation
Papayannopoulou, T., & Migliaccio, A. R. (2017) · Elsevier eBooks · doi:10.1016/b978-0-323-35762-3.00026-3 · Cited by 23
Huang, C., Li, Q., & Li, J. (2022) · Medical Review · doi:10.1515/mr-2022-0029 · Cited by 20
“Disrupted BCL11A expression showed therapeutic potential but negatively affectedB-cell differentiationandHSCengraftment [177, 187].”
BackgroundGeneration of a genomic reporter assay system for analysis of γ‐ and β‐globin gene regulation
Chan, K., Xu, J., Wardan, H., McColl, B., Orkin, S. H., & Vadolas, J. (2012) · The FASEB Journal · doi:10.1096/fj.11-199356 · Cited by 23
Self-citationEguchi, A., Lee, G. O., Wan, F., Erwin, G. S., & Ansari, A. Z. (2014) · Biochemical Journal · doi:10.1042/bj20140400 · Cited by 20
Goodman, S. R., Pace, B. S., Hansen, K. C., D’Alessandro, A., Xia, Y., Daescu, O., & Glatt, S. J. (2016) · Experimental Biology and Medicine · doi:10.1177/1535370216640150 · Cited by 21
“Later studies confirmed BCL11A gene inactivation in sickle cell mice inhibited developmentally regulated g-globin gene silencing and improved several hematologic parameters including renal function and spleen size in these animals.(49) Several groups have shed light on the mechanisms by which BCL11A represses g-globin…”
Gene Addition Strategies for β-Thalassemia and Sickle Cell Anemia
Dong, A., & Rivella, S. (2017) · Advances in experimental medicine and biology · doi:10.1007/978-1-4939-7299-9_6 · Cited by 21
“Xu and colleagues were able to demonstrate that affecting BCL11A alone was able to increase endogenous gamma-globin expression and ameliorate the sickle cell phenotype in mice [62].”
BackgroundAntony, J. S., Haque, A. K. M. A., Lamsfus‐Calle, A., Daniel-Moreno, A., Mezger, M., & Kormann, M. (2018) · Advances in Cell and Gene Therapy · doi:10.1002/acg2.10 · Cited by 21
“The current reactivation therapy is focused on BCL11A, a direct transcriptional repressor of HbF, as it is a potential therapeutic target for b-hemoglobinopathies.(34) Importantly, the gene disruption strategy is more favored by the nonhomologous end-join-”
Background3′HS1 CTCF binding site in human β-globin locus regulates fetal hemoglobin expression
Himadewi, P., Wang, X. Q. D., Feng, F., Gore, H., Liu, Y., Yu, L., Liu, J., Kurita, R., Nakamura, Y., Pfeifer, G., et al. (2021) · eLife · doi:10.7554/elife.70557 · Cited by 20
“As such, multiple genome- editing strategies have been proposed to mimic HPFH as a treatment for hemoglobinopathies (Bauer et al., 2012; Breda et al., 2016; Sankaran et al., 2008; Sankaran et al., 2011; Sankaran et al., 2009; Traxler et al., 2016; Xu et al., 2011; Ye et al., 2016; Zeng et al., 2020).”
Leisi, R., Nordheim, M. V., Kempf, C., & Ros, C. (2015) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.5b00321 · Cited by 19
Management of Non-Transfusion-Dependent Thalassemia: A Practical Guide
Taher, A. T., & Cappellini, M. D. (2014) · Drugs · doi:10.1007/s40265-014-0299-0 · Cited by 20
“Interference with (reversal of) developmental fetal hemoglobin silencing corrected the anemia in animal studies [65], while gene therapy has shown similar benefits in human case reports [66].”
“Packaging” of fetal hemoglobin in sickle cell anemia
Buchanan, G. R. (2014) · Blood · doi:10.1182/blood-2013-11-539981 · Cited by 19
The Fetal-to-Adult Hemoglobin Switch — Mechanism and Therapy
Orkin, S. H. (2025) · New England Journal of Medicine · doi:10.1056/nejmra2405260 · Cited by 21
Self-citationMnika, K., Pule, G. D., Dandara, C., & Wonkam, A. (2016) · OMICS A Journal of Integrative Biology · doi:10.1089/omi.2016.0105 · Cited by 19
“Interestingly, the expression of these modifiers is amenable to therapeutic manipulation (Bukar et al., 2013; Canver et al., 2015; Xu et al., 2011), leading to new hope for treatment routes for SCD (Orkin, 2016).”
A Practical Guide to Genome Editing Using Targeted Nuclease Technologies
Porter, S. N., Levine, R. M., & Pruett‐Miller, S. M. (2019) · Comprehensive physiology · doi:10.1002/cphy.c180022 · Cited by 18
Transcriptional silencing of fetal hemoglobin expression by NonO
Li, X., Chen, M., Liu, B., Lu, P., Lv, X., Zhao, X., Cui, S., Xu, P., Nakamura, Y., Kurita, R., et al. (2021) · Nucleic Acids Research · doi:10.1093/nar/gkab671 · Cited by 18
“The mouse and human (cid:2) -globin-like loci are highly conserved, and share many functional elements (7,48).”
Sickle cell disease: looking back but towards the future
Cançado, R. D. (2012) · Revista Brasileira de Hematologia e Hemoterapia · doi:10.5581/1516-8484.20120041 · Cited by 18
“in the laboratory of Stuart Orkin at Harvard Medical School have identified the BCL11A as a pharmacologic target for the treatment of patients with SCD((12)).”
BackgroundWang, J., Zhang, L., Cui, X., Xu, X., Guo, R., Li, K., Zhang, L., Xu, B., Jiang, C., & Yu, Y. (2025) · Science Immunology · doi:10.1126/sciimmunol.adr2041 · Cited by 17
Chami, N., & Lettre, G. (2014) · Genes · doi:10.3390/genes5010051 · Cited by 19
“Since then, we have learned that BCL11A is a potent transcriptional repressor of γ-globin gene expression and that its inactivation in the erythroid lineage can treat a sickle cell disease mouse model through re-activation of HbF production [69,70].”
BackgroundRecent advances in globin research using genome‐wide association studies and gene editing
Orkin, S. H. (2016) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.13001 · Cited by 17
Self-citationDevelopmental cues license megakaryocyte priming in murine hematopoietic stem cells
Kristiansen, T. A., Zhang, Q., Vergani, S., Boldrin, E., Krausse, N., André, O., Nordenfelt, P., Sigvardsson, M., Bryder, D., Ungerbäck, J., et al. (2022) · Blood Advances · doi:10.1182/bloodadvances.2021006861 · Cited by 21
Wonkam, A., Bitoungui, V. J. N., & Ngogang, J. Y. (2015) · Public Health Genomics · doi:10.1159/000431020 · Cited by 17
Nwankwo, J. O., Lei, J.-X., Xu, J., Rivera, A., Gupta, K., & Chishti, A. H. (2016) · Haematologica · doi:10.3324/haematol.2016.148106 · Cited by 16
“The first gene BCL11A was deleted in both Townes and Berkeley mice.(10) The ultimate goal of any sickle cell therapy is the reduction of chronic pain and episodes of acute pain crises in patients with sickle cell disease.”
BackgroundSelf-citationEpigenomic analysis of KLF1 haploinsufficiency in primary human erythroblasts
Heshusius, S., Grech, L., Gillemans, N., Brouwer, R. W. W., den Dekker, A. T., van IJcken, W. F. J., Nota, B., Felice, A. E., van Dijk, T. B., Lindern, M. V., et al. (2022) · Scientific Reports · doi:10.1038/s41598-021-04126-6 · Cited by 17
Targeting fetal hemoglobin expression to treat β hemoglobinopathies
Steinberg, M. H. (2022) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2022.2066519 · Cited by 19
Inhibition of LSD1 by small molecule inhibitors stimulates fetal hemoglobin synthesis
Le, C. Q., Myers, G., Habara, A. H., Jearawiriyapaisarn, N., Murphy, G. J., Chui, D. H. K., Steinberg, M. H., Engel, J. D., & Cui, S. (2019) · Blood · doi:10.1182/blood.2018892737 · Cited by 16
Transcriptional Repressor BCL11A in Erythroid Cells
Zheng, G., & Orkin, S. H. (2024) · Advances in experimental medicine and biology · doi:10.1007/978-3-031-62731-6_9 · Cited by 15
Self-citationFinotti, A., Gasparello, J., Breveglieri, G., Cosenza, L. C., Montagner, G., Bresciani, A., Altamura, S., Bianchi, N., Martini, E., Gallerani, E., et al. (2015) · Experimental Hematology · doi:10.1016/j.exphem.2015.08.011 · Cited by 15
Long noncoding RNAs in erythropoiesis
Gallagher, P. G. (2014) · Blood · doi:10.1182/blood-2013-12-538306 · Cited by 15
Rafii, H., Bernaudin, F., Rouard, H., Vanneaux, V., Ruggeri, A., Cavazzana, M., Gauthereau, V., Stanislas, A., Benkerrou, M., de Montalembert, M., et al. (2017) · Haematologica · doi:10.3324/haematol.2016.163055 · Cited by 17
“8x10(5)) CD34 cells, with a median recipient body weight of 22 kg (14-56) for the 28 patients transplanted (Table 4).”
BackgroundGWAS to Therapy by Genome Edits?
Hardison, R. C., & Blobel, G. A. (2013) · Science · doi:10.1126/science.1245813 · Cited by 15
Metadata
- Authors
- Xu, J., Peng, C., Sankaran, V. G., Shao, Z., Esrick, E. B., Chong, B. G., Ippolito, G. C., Fujiwara, Y., Ebert, B. L., Tucker, P. W., & Orkin, S. H.
- Affiliations
- Boston Children's Hospital (US)
- Broad Institute (US)
- Brigham and Women's Hospital (US)
- The University of Texas at Austin (US)
- Corresponding author
- Peng, Cong
- Sankaran, Vijay G.
- Orkin, Stuart H.
- ORCID
- Venue
- Science
- Published
- 2011-11-18
- Volume
- 334
- Issue
- 6058
- Pages
- 993-996
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- PMC
- PMC3746545
- OpenAlex
- W2033380734
- Cited by
- 326
- References
- 45
- Citations by year
- 2026: 10 · 2025: 15 · 2024: 16 · 2023: 13 · 2022: 18 · 2021: 20 · 2020: 22 · 2019: 18 · 2018: 25 · 2017: 24 · 2016: 42 · 2015: 26 · 2014: 23 · 2013: 32 · 2012: 19
- Type
- journal article
- Language
- en
- Open access
- green
- europepmc.org
- Locations
- Science (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- Howard Hughes Medical Institute
- National Cancer Institute (T32CA009172)
- National Institute of Diabetes and Digestive and Kidney Diseases (K01DK093543)
- Topics
- Health Sciences › Medicine › Genetics (clinical) › Hemoglobinopathies and Related Disorders
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Hemoglobin structure and function
- Health Sciences › Medicine › Hematology › Hematopoietic Stem Cell Transplantation
- Keywords
- sickle cell disease, fetal hemoglobin, BCL11A, beta-thalassemia, transgenic mice, therapeutic target, erythropoiesis
- MeSH terms
- Anemia, Sickle Cell, Animals, Carrier Proteins, DNA-Binding Proteins, Embryo, Mammalian, Fetal Hemoglobin, Gene Expression Regulation, Histones, Humans, Mice, Transgenic, Nuclear Proteins, Repressor Proteins, Mice, Knockout, DNA Methylation, Gene Silencing, Erythroid Cells, Epigenesis, Genetic, Mice, gamma-Globins, Molecular Targeted Therapy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.